Nussbaum Ran

CIK 00016098059 companiesLEXINGTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001609805

Recent Transactions

50 trades

Conversion
LB PHARMACEUTICALS INC$LBRX
Series C Preferred Stock
2025-09-12−10,000,000→ 0 total
Purchase
LB PHARMACEUTICALS INC$LBRX
Common Stock
2025-09-12$15.00/sh+1,000,000→ 1,411,681 total
Conversion
LB PHARMACEUTICALS INC$LBRX
Common Stock
2025-09-12+411,681→ 411,681 total
Award
LB PHARMACEUTICALS INC$LBRX
Stock Option (Right to Buy)
2025-09-10+22,449→ 22,449 total
Award
Keros Therapeutics, Inc.$KROS
Stock Option (right to buy)
2025-06-04+10,500→ 10,500 total
Award
Keros Therapeutics, Inc.$KROS
Common Stock
2025-06-04+5,250→ 5,250 total
Award
Keros Therapeutics, Inc.$KROS
Stock Option (right to buy)
2024-05-30+10,000→ 10,000 total
Award
Keros Therapeutics, Inc.$KROS
Stock Option (right to buy)
2023-06-06+10,000→ 10,000 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Common Stock
2022-11-29$0.00/sh−3,539→ 2,284,612 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Common Stock
2022-11-29$0.00/sh−1,914→ 1,226,412 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Call Options (obligation to sell)
2022-11-29−1,914→ 0 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Common Stock
2022-11-29$0.00/sh−1,723→ 1,121,045 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Call Options (obligation to sell)
2022-11-29−1,723→ 0 total
Exercise of In-Money
Keros Therapeutics, Inc.$KROS
Call Options (obligation to sell)
2022-11-29−3,539→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Ordinary Shares
2022-10-21$5.94/sh+47,999→ 1,481,927 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-10-21−32,723→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Ordinary Shares
2022-10-21$5.94/sh+47,999→ 1,485,168 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-10-21−15,276→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-10-21−32,723→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-10-21−15,276→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Ordinary Shares
2022-06-16$5.00/sh+2,211→ 1,437,169 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-06-16−2,211→ 0 total
Award
Eloxx Pharmaceuticals, Inc.
Stock Options (Right to Buy)
2022-06-15+20,000→ 20,000 total
Award
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-06-08+6,817→ 6,817 total
Award
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-06-08+3,183→ 3,183 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-06-06−1,030→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Ordinary Shares
2022-06-06$5.00/sh+1,030→ 1,434,958 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Ordinary Shares
2022-06-06$5.00/sh+1,030→ 1,433,928 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2022-06-06−1,030→ 0 total
Award
Keros Therapeutics, Inc.$KROS
Stock Options (right to buy)
2022-06-01+8,293→ 8,293 total
Award
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2021-06-07+3,183→ 3,183 total
Award
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2021-06-07+6,817→ 6,817 total
Award
Keros Therapeutics, Inc.$KROS
Stock Option (right to buy)
2021-06-01+8,293→ 8,293 total
Award
Eloxx Pharmaceuticals, Inc.
Stock Option (Right to Buy)
2021-05-19+20,000→ 20,000 total
Purchase
Eloxx Pharmaceuticals, Inc.
Common Stock
2021-05-13$1.35/sh+592,592→ 616,592 total
Purchase
Eloxx Pharmaceuticals, Inc.
Common Stock
2021-05-13$1.35/sh+1,280,624→ 1,791,470 total
Purchase
Eloxx Pharmaceuticals, Inc.
Common Stock
2021-05-13$1.35/sh+1,422,222→ 1,989,551 total
Purchase
Eloxx Pharmaceuticals, Inc.
Common Stock
2021-05-13$1.35/sh+2,630,487→ 3,679,797 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2021-03-25−2,211→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Ordinary Shares
2021-03-25$5.00/sh+2,211→ 1,433,928 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2021-03-25−1,030→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Ordinary Shares
2021-03-25$5.00/sh+1,030→ 1,431,717 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Stock Option (right to buy)
2021-03-24−1,030→ 0 total
Exercise/Conversion
UroGen Pharma Ltd.$URGN
Ordinary Shares
2021-03-24$5.00/sh+1,030→ 1,465,199 total
Disposition to Issuer
Prevail Therapeutics Inc.
Stock Option (Right to Buy)
2021-01-22−17,000→ 0 total
Disposition from Tender
Prevail Therapeutics Inc.
Common Stock
2021-01-22−1,576,881→ 0 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-11-17$50.00/sh+14,400→ 1,228,326 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-11-17$50.00/sh+6,000→ 155,262 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-11-17$50.00/sh+26,634→ 2,288,151 total
Purchase
Keros Therapeutics, Inc.$KROS
Common Stock
2020-11-17$50.00/sh+12,966→ 1,122,768 total

Companies

Recent Filings

Address

C/O KEROS THERAPEUTICS, INC. 1050 WALTHAM STREET, SUITE 302

LEXINGTON, MA, 02421

View on SEC.gov